However, the lack of data on CD5 expression patterns in CTCL, combined with the known prevalence of antigen loss in this disease, presents an opportunity to evaluate CD5 expression and its relationship to the outcome of CD5-directed CAR T-cell therapy in this patient population. Here, CD5 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.